Design and synthesis of a water-soluble taxol analogue: Taxol-sialyl conjugate

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 1, 1998, Pages 113-116

  Takahashi, Takashi ^a   Tsukamoto, Hirokazu ^a   Yamada, Haruo ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; PACLITAXEL DERIVATIVE; SIALIC ACID;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SOLUBILITY; DRUG SYNTHESIS; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEURAMINIDASE; PACLITAXEL; PRODRUGS; SOLUBILITY; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0032488645     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10189-5     Document Type: Article

References (12)

1. 1) Rowinski, E. K.; Donehower, R. C. Pharmacol. Ther. 1991, 52, 35-84.
2. 2) Nicolaou, K. C.; Guy, R. K.; Pitsinos, E. N.; Wrasidlo, W. Angew. Chem. Int. Ed. Engl. 1994, 33, 1583-1587.
3. 3) Lataste, H.; Senilh, V.; Wright, M.; Guénard, D.; Potier, P. Proc. Natl. Acad. Sci. USA 1984, 81, 4090-4094.
4. 4) Deutsch, H. M.; Glinski, J. A.; Hernandez, M.; Haugwitz, R. D.; Narayanan, V. L.; Suffness, M.; Zalkow, L. H. J. Med. Chem. 1989, 32, 788-792.
5. 5) Greenwald, R. B.; Pendri, A.; Bolikal. D. J. Org. Chem. Soc. 1995, 60, 331-336.
6. 6) Suzuki, Y.; Nagano, Y.; Kato, H.; Matsumoto, M.; Nerome, K.; Nakajima, K.; Nobusawa, E. J. Biol. Chem. 1986, 261, 17057.
7. 7) a) Schengrund, C.-L.; Lausch, R. N.; Rosenberg, A. J. Biol. Chem. 1973, 248, 4424-4428.
8. b) Schengrund, C.-L.; Duff, R.; Rosenberg, A. Virology 1974, 58, 595-599.
9. 8) Hasegawa, A.; Ohki, H.; Nagahama, T.; Ishida, H.; Kiso, M. Carbohydr. Res. 1991, 212, 277-281.
10. 9) Hasegawa, A.; Nagahama, T.; Ohki, H.; Hotta, K.; Ishida, H.; Kiso, M. J. Carbohydr. Chem. 1991, 10, 493-498.
11. 10) Application of PM3 calculations to the α- and β-sulfonium intermediates (all hydroxy groups and side chain at C5 in sialic acid were replaced by hydrogens for simplicity of calculations ) revealed that the energy of β-sulfonium intermediate 13A was calculated to be 1.2 kcal/mol more stable than that of α-sulfonium intermediate 13B. (equation presented) β-sulfonium intermediate 13A α-sulfonium intermediate 13A
12. 26Na m/z=1342 (M+Na). Bioorganic & Medicinal Chemistry